Glycosylated fusion protein, nucleic acid molecule, expression vector, host cell and use thereof

By modifying the mouse Fc fragment with amino acid mutations and glycosylation, the prepared fusion protein binds to DC cells and activates T cells, solving the problem of insufficient immune response in existing HBV vaccines in chronic infection and achieving effective immune activation against HBV.

WO2026129723A1 Publication Date: 2026-06-25CHIMIGEN BIOMEDICAL (CHENGDU) CO LTD
22 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2025/117662
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-12-20
Filing Date
2025-08-28
Publication Date
2026-06-25

AI Technical Summary

Technical Problem

Existing HBV vaccines are effective in preventing infection, but ineffective in eradicating chronic infection. Furthermore, in chronic HBV infection, viral antigens are recognized as "self" substances, failing to elicit an effective intracellular antigen-specific T-cell immune response.

Method used

A glycosylated fusion protein was prepared by mutating the mouse Fc fragment with amino acids and glycosylating it with non-mammalian molecules. This protein then binds to dendritic cells (DCs), activates DCs, and promotes the proliferation and activation of specific T cells.

Benefits of technology

It enhances the binding ability to dendritic cells, promotes the proliferation and activation of specific T cells, improves the efficacy of the immune response to HBV, and has the potential to treat chronic HBV infection.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Provided in the present application are a glycosylated fusion protein, a nucleic acid molecule, an expression vector, a host cell and the use thereof. A first aspect of the present application provides the glycosylated fusion protein, comprising a murine Fc variant and a hepatitis B virus antigen, wherein the murine Fc variant is obtained by performing amino acid mutation and non-mammalian glycosylation modification on a murine Fc fragment, the murine Fc variant comprises at least one of alanine at position 223, alanine at position 228, alanine at position 230, leucine at position 330, and glutamic acid at position 332, the glycosylation modification does not comprise sialic acid modification, and the positions are numbered according to the EU numbering system. The fusion protein can bind to DC cells and activate DC cells, and thus promote the proliferation and activation of specific T cells.
Need to check novelty before this filing date? Find Prior Art